Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDP.L Regulatory News (IDP)

  • There is currently no data for IDP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

10 Jul 2020 07:00

RNS Number : 5987S
InnovaDerma PLC
10 July 2020
 

 LEI: 213800WRAP6W8VDL6B38

InnovaDerma PLC

("InnovaDerma" or the "Group")

Trading Statement

InnovaDerma (LSE: IDP), a UK developer of beauty, personal care and life science products, provides a trading update for the 12 months ended 30 June 2020. 

The welfare of our employees during Covid-19 continues to be our priority. With flexible working procedures and additional communication measures in place, our colleagues continued to provide uninterrupted services to our customers. As per our trading update of late May, we traded strongly online despite experiencing a material decline in contribution from our bricks and mortar retail channels. Increased demand, particularly for Skinny Tan in the UK and the US, saw a healthy growth in customer traffic with an increase in our client list of c.27% and c.65% respectively.

 

The Group expects revenues to be up 2.3% against the previous year at c. £13.2m (2019: £12.9m). The significant impact of COVID-19 and the combination of higher on-line advertising costs, lower margins of DTC product bundles and the closure of our bricks and mortar retail channels has unfortunately impacted profitability. It is estimated that the aggregate cost of these related factors in the normally profit weighted second half of the year has been in excess of £0.9m. As a result, the Group expects to make a much-reduced profit compared to the previous year.

 

The cost of advertising on Facebook rose suddenly and sharply in the last quarter of the financial year which was primarily the lock-down period. This has impacted our return on advertising spend as Facebook's charges work through an automated bidding system, the algorithms of which determine costs which, in turn, rise when there is seller demand for advertising to specific audiences. The impact of COVID-19 has also driven many traditional businesses to this dominant platform for online visibility and revenues. This has inflated the rates at which we are required to compete against, and the continuous fluctuations of these rates intensified significantly during lock-down, which meant our profitability was difficult to predict.

 

We experienced these fluctuations with Facebook and other platforms over the last 12 months, and in order to counter this, we placed strategic importance on the diversification of our advertising channels and invested in our own Artificial Intelligence software which will become more effective over time as it learns more about customers. This investment has, in part, helped to offset the previous spike in costs on Facebook. The continuous diversification of platforms is of priority to the Group and will help improve our return on advertising spend.

 

Cash management has been a key area of focus and the Group has benefitted from strong cash flows. As at 30 June 2020, the Group had c.£1.3m in cash and cash equivalents and continues to be debt free.

The business has performed resiliently during the pandemic and the subsequent impact on earnings is disappointing. However, the business is financially sound with a strong solid capital structure and operating platform that is well-placed to respond to periods of uncertainty. As lock-down eases across many countries, the Board continues to assess opportunities to strengthen the overall business with a clear focus on generating better returns on investment. We remain well-positioned and look forward to updating our shareholders at our final results which will be announced in September 2020.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Further enquiries

 

InnovaDerma

Joe Bayer

Kieran Callan c/o TB Cardew

 

+61 (0)3 9863 8030

+44 (0)20 7930 0777

finnCap Ltd

Geoff Nash/Kate Bannatyne

Alice Lane/Manasa Patil - Corporate Broking

 

+44 (0)207 220 0500

www.finncap.com

TB Cardew

Shan Shan Willenbrock/Tom Allison

Olivia Rosser

 

+ 44 (0)20 7930 0777

innovaDerma@tbcardew.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKCBDOBKDBOK
Date   Source Headline
12th Jan 20227:00 amRNSTrading Update
6th Jan 20222:06 pmRNSSecond Price Monitoring Extn
6th Jan 20222:01 pmRNSPrice Monitoring Extension
4th Jan 20227:00 amRNSAcquisition of Remaining Shareholding - Skinny Tan
24th Dec 202112:44 pmRNSHolding(s) in Company
24th Dec 202112:41 pmRNSDirector/PDMR Shareholding
23rd Dec 20211:22 pmRNSNotice of AGM and Posting of Annual Report
20th Dec 20219:10 amRNSFinal Results
6th Dec 20217:00 amRNSJV established to accelerate growth of Prolong
22nd Oct 20217:00 amRNSExtension to Annual Report & Accounts Publication
12th Oct 20217:00 amRNSAppointment of Skinny Tan brand ambassador
16th Sep 202111:17 amRNSDirector/PDMR Shareholding
15th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20216:24 pmRNSHolding(s) in Company
7th Sep 202110:35 amRNSDirector/PDMR Shareholding
2nd Sep 20217:00 amRNSCorporate Update
8th Jul 20217:00 amRNSTrading Statement
5th Jul 20217:00 amRNSChange of Auditor
11th May 20216:15 pmRNSDirector/PDMR Shareholding
7th May 202111:05 amRNSSecond Price Monitoring Extn
7th May 202111:00 amRNSPrice Monitoring Extension
4th May 20215:12 pmRNSHolding(s) in Company
29th Apr 202112:24 pmRNSResult of Open Offer and General Meeting
29th Apr 20217:00 amRNSGeneral Meeting and Trading Statement
19th Apr 20214:41 pmRNSSecond Price Monitoring Extn
19th Apr 20214:35 pmRNSPrice Monitoring Extension
16th Apr 202111:00 amRNSDirector/PDMR Shareholding
12th Apr 20216:19 pmRNSPublication of Prospectus
12th Apr 20217:00 amRNSExpected Timetable of Events
31st Mar 20217:00 amRNSInterim Results
22nd Mar 20212:25 pmRNSNotice of Results, Prospectus and General Meeting
24th Feb 20215:09 pmRNSForm 8.3 - Offeree Innovaderma
24th Feb 20214:47 pmRNSForm 8.3 - InnovaDerma PLC
23rd Feb 20211:51 pmRNSForm 8.3 - InnovaDerma PLC
22nd Feb 20214:48 pmRNSForm 8.3 - Innovaderma
19th Feb 20214:13 pmRNSForm 8.3 - Innovaderma PLC
18th Feb 20217:00 amRNSForm 8.3 - InnovaDerma PLC
17th Feb 20215:23 pmRNSForm 8.3 - InnovaDerma PLC
17th Feb 202112:37 pmRNSForm 8.3 - InnovaDerma
16th Feb 20216:23 pmRNSForm 8.3 - InnovaDerma PLC
16th Feb 202112:33 pmRNSForm 8.3 - InnovaDerma
16th Feb 202110:52 amRNSForm 8.3 - Innovaderma Plc
16th Feb 202110:06 amRNSForm 8.3 - Innovaderma PLC
16th Feb 20219:05 amBUSForm 8.3 - INNOVADERMA PLC - AMENDMENT
15th Feb 20216:12 pmRNSForm 8.3 - InnovaDerma
15th Feb 20215:03 pmRNSForm 8.3 - InnovaDerma Plc
15th Feb 20215:02 pmRNSHolding(s) in Company
15th Feb 20214:47 pmRNSForm 8 (OPD) - InnovaDerma plc
15th Feb 20213:40 pmRNSForm 8.3 - InnovaDerma PLC
15th Feb 20212:54 pmRNSForm 8.3 - InnovaDerma PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.